<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1504">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597827</url>
  </required_header>
  <id_info>
    <org_study_id>38RC20.282</org_study_id>
    <secondary_id>2020-A02236-33</secondary_id>
    <nct_id>NCT04597827</nct_id>
  </id_info>
  <brief_title>Metacognition in Semantic Dementia: Comparison With Alzheimer's Disease</brief_title>
  <acronym>META-DEM</acronym>
  <official_title>Metacognition in Semantic Dementia: Comparison With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at exploring patients' ability to monitor their own memory performance&#xD;
      depending on their primary deficit and the type of memory involved in the criterion task. The&#xD;
      goal is to evaluate if semantic dementia (SD) and Alzheimer's disease (AD) differently affect&#xD;
      patients' awareness of their memory abilities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who will give their informed non-opposition will be included. Participants will&#xD;
      undergo 6 metacognitive tasks in which they will be tested on newly learnt information (i.e.,&#xD;
      episodic memory) or prior knowledge (i.e., semantic memory) and asked to evaluate their&#xD;
      performance either prior or after the test. Correlation between their evaluation and their&#xD;
      actual performance will be measured. Performance and correlations will be compared across&#xD;
      groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Metacognitive bias on the episodic predictive judgment task</measure>
    <time_frame>End of study : around May 2022</time_frame>
    <description>Metacognitive bias will be assessed by subtracting the mean proportion of the metacognitive judgments to the actual memory performance. Bias will range from -1 (underestimation) to 1 (overestimation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metacognitive accuracy on the episodic predictive judgment task</measure>
    <time_frame>End of study : around May 2022</time_frame>
    <description>Metacognitive accuracy will be assessed by calculating a gamma correlation for each participant. Metacognition accuracy allows to evaluate people's ability to discriminate correct responses from incorrect responses. Gamma correlation range from -1 to 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metacognitive bias on the semantic predictive judgment task</measure>
    <time_frame>End of study : around May 2022</time_frame>
    <description>Metacognitive bias will be assessed by subtracting the mean proportion of the metacognitive judgments to the actual memory performance. Bias will range from -1 (underestimation) to 1 (overestimation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metacognitive accuracy on the semantic predictive judgment task</measure>
    <time_frame>End of study : around May 2022</time_frame>
    <description>Metacognitive accuracy will be assessed by calculating a gamma correlation for each participant. Metacognition accuracy allows to evaluate people's ability to discriminate correct responses from incorrect responses. Gamma correlation range from -1 to 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metacognitive bias on episodic global judgment task</measure>
    <time_frame>End of study : around May 2022</time_frame>
    <description>Metacognitive bias will be assessed by subtracting the mean proportion of the metacognitive judgments to the actual memory performance. Bias will range from -1 (underestimation) to 1 (overestimation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metacognitive bias on semantic global judgment task</measure>
    <time_frame>End of study : around May 2022</time_frame>
    <description>Metacognitive bias will be assessed by subtracting the mean proportion of the metacognitive judgments to the actual memory performance. Bias will range from -1 (underestimation) to 1 (overestimation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metacognitive bias on the episodic retrospective judgment task</measure>
    <time_frame>End of study : around May 2022</time_frame>
    <description>Metacognitive bias will be assessed by subtracting the mean proportion of the metacognitive judgments to the actual memory performance. Bias will range from -1 (underestimation) to 1 (overestimation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metacognitive accuracy on the episodic retrospective judgment task</measure>
    <time_frame>End of study : around May 2022</time_frame>
    <description>Metacognitive accuracy will be assessed by calculating a gamma correlation for each participant. Metacognition accuracy allows to evaluate people's ability to discriminate correct responses from incorrect responses. Gamma correlation range from -1 to 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metacognitive bias on the semantic retrospective judgment task</measure>
    <time_frame>End of study : around May 2022</time_frame>
    <description>Metacognitive bias will be assessed by subtracting the mean proportion of the metacognitive judgments to the actual memory performance. Bias will range from -1 (underestimation) to 1 (overestimation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metacognitive accuracy on the semantic retrospective judgment task</measure>
    <time_frame>End of study : around May 2022</time_frame>
    <description>Metacognitive accuracy will be assessed by calculating a gamma correlation for each participant. Metacognition accuracy allows to evaluate people's ability to discriminate correct responses from incorrect responses. Gamma correlation range from -1 to 1.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Semantic Dementia</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Semantic dementia</arm_group_label>
    <description>Diagnosis of semantic dementia (revised criteria Moreaud et al., 2008; based on Neary et al., 1998)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <description>NIAAA 2011 criteria</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>MMSE above 27, no neurological or psychiatric disorder</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metacognition tests</intervention_name>
    <description>Test on episodic or semantic memory</description>
    <arm_group_label>Alzheimer's disease</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Semantic dementia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Alzheimer's disease will be patients at the CHU of Grenoble.&#xD;
&#xD;
        Patients with Alzheimer's disease will be recruited in the CHU Grenoble, CHU Angers, CHU&#xD;
        Bordeaux, CHU Colmar, CHU Lyon, CHU Rennes and CHUV Lausanne.&#xD;
&#xD;
        Controls will be recruited via the database &quot;Seniors pour la Science &quot;,&#xD;
        https://seniorspourlascience.fr/&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  native French-speakers&#xD;
&#xD;
          -  normal or corrected-to-normal vision&#xD;
&#xD;
          -  for patients ONLY : doctor-approved diagnosis of semantic dementia or Alzheimer's&#xD;
             disease&#xD;
&#xD;
          -  for healthy participants ONLY: score above 27 on the MMSE&#xD;
&#xD;
          -  non-opposition in participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other neurological/ psychiatric disorder, or cognitive disorder that might affect&#xD;
             general cognition&#xD;
&#xD;
          -  drug or alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier MOREAUD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier MOREAUD</last_name>
    <phone>(33)4.76.76.57.90</phone>
    <email>omoreaud@chu-grenoble.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Céline SOUCHAY</last_name>
    <phone>33 (0)6 72 23 12 97</phone>
    <email>celine.souchay@univ-grenoble-alpes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49 933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédérique ETCHARRY-BOUYX</last_name>
      <phone>02 41 35 46 14</phone>
      <email>FrEtcharry-Bouyx@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie AURIACOMBE</last_name>
      <phone>+33 (0)5 57 82 01 16</phone>
      <email>sophie.auriacombe@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Neurologique de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard CROISILE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Civils Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François SELLAL</last_name>
      <phone>(33)3.89.12.41.50</phone>
      <email>francois.sellal@ch-colmar.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier MOREAUD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge BELLIARD</last_name>
      <phone>33 (0)2 99 28 42 94</phone>
      <email>serge.belliard@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier ROUAUD</last_name>
      <email>Olivier.Rouaud@chuv.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>May 6, 2022</last_update_submitted>
  <last_update_submitted_qc>May 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

